Quoin Pharmaceuticals Reports $3.95 Million Net Loss and Increased R&D Expenses in Latest Quarter

Quoin Pharmaceuticals Ltd. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of approximately $3.95 million for the third quarter, compared to a loss of $2.35 million in the same period last year, marking an increase of 68% year-over-year. For the nine months ending September 30, 2025, the total net loss reached approximately $11.46 million, up from $6.65 million during the same timeframe in 2024. The increase in losses is attributed primarily to a substantial rise in research and development expenses, which surged by 111% to $2.28 million in the third quarter, driven by heightened external expenditures related to clinical studies for its lead product, QRX003.

The company’s total operating expenses for the third quarter amounted to $4.02 million, a 59% increase from $2.53 million in the prior year. General and administrative expenses also rose by 20% to $1.74 million, reflecting increased payroll and consulting costs. As of September 30, 2025, Quoin's cash and cash equivalents stood at $1.83 million, a significant decrease from $3.62 million at the end of 2024. The company’s total assets dropped to $6.42 million from $15.71 million, while total liabilities increased to $7.64 million, resulting in a shareholders' equity deficit of $1.21 million.

Strategically, Quoin has made notable advancements in its clinical development efforts. The company is currently conducting pivotal clinical studies for QRX003, aimed at treating Netherton Syndrome, with six clinical sites opened in the U.S. and additional sites in Europe and the Middle East. Furthermore, Quoin has entered into nine commercial partnerships for QRX003 across 61 countries, expanding its reach beyond its core markets in the U.S., Western Europe, and Japan. The company has also secured Orphan Drug Designation from the FDA for QRX003, which provides various benefits, including market exclusivity upon approval.

In terms of operational metrics, Quoin has seen a significant increase in its employee headcount, reflecting its commitment to advancing its clinical programs. The company has also engaged in a private placement, raising approximately $15 million in October 2025, which is expected to support its ongoing research and development activities. However, Quoin acknowledges the need for additional financing to sustain its operations until it achieves commercial profitability, which remains uncertain. The company’s management has indicated that it will continue to explore various funding avenues, including equity offerings and strategic partnerships, to support its business objectives moving forward.